Skip to main content

Gujarat Themis Biosyn Limited (GUJTHEM.BO)

Bombay Stock Exchange (India) Healthcare Medical - PharmaceuticalsView data quality →
45.6Fair

ValueMarkers Composite Index

Top 15%#38,222 of 44,707
Overvalued

417% above intrinsic value ($1)

UndervaluedFair ValueOvervalued
Piotroski
3/9
Weak
Beneish
-4.62
Low Risk
Altman
37.73
Safe
DCF Value
$1
Overvalued
ROIC
13.8%
Adequate
P/E
64.5
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Gujarat Themis Biosyn Limited (GUJTHEM.BO) — VMCI valuation read

Composite valuation read on GUJTHEM.BO: VMCI 46/100 against a Healthcare sector median of 50. The 4-point below-median print is the headline number for Gujarat Themis Biosyn Limited, and at the mid-cap tier it reflects how the five pillars combine into a single decision-grade score.

Trailing 30-day insider activity for GUJTHEM.BO: nothing material on SEC EDGAR. With the Form 4 channel quiet, the price-vs-DCF gap and the trailing margin trend carry more weight in the active read.

**Investor frame.** Value, quality, risk in three lines on GUJTHEM.BO: GUJTHEM.BO trades at 19.0x earnings, 6% above the Healthcare median of 18.0x; ROIC of 9.0% trails the Healthcare median (10.0%) by 1.0pp; net debt to EBITDA of 1.7x is the rate-sensitivity line to watch. EV/EBITDA at 14.0x versus 12.0x for Healthcare closes the value frame.

GUJTHEM.BO fell 0.6% over the trailing 7 days, with a +1.9% read on a 30-day basis.

Gujarat Themis Biosyn Ltd. operates as a pharmaceutical company. The firm engages in the manufacture of drugs. Its products include Rifamycin and Lovastatin. The company was founded on December 11, 1981 and is headquartered in Mumbai, India.

CEO: Sachin Dinesh Patel159 employeesINwww.gtbl.in

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in GUJTHEM.BO’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.